Literature DB >> 15740862

Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat.

Anne Lespine1, Michel Alvinerie, Jean-François Sutra, Isabelle Pors, Christophe Chartier.   

Abstract

The tissue concentration and efficacy of ivermectin after per os and subcutaneous administration were compared in goats experimentally infected with Trichostrongylus colubriformis (ivermectin-susceptible strain, INRA). Infected goats (n = 24) were treated per os (n = 9) or subcutaneously (n = 9) with ivermectin, 0.2 mg/kg, or kept as not treated controls. The faecal egg counts and small intestine worm counts were determined. Ivermectin concentration was measured in the plasma, gastrointestinal tract, lung, skin or hair, liver and adipose tissues at 0, 2, 7 and 17 days post-treatment. The efficacy of ivermectin against T. colubriformis infection in goat was 98.7 and 99.9% for subcutaneous and oral administration, respectively. Ivermectin concentration declined with time and only residual concentration was measured at 17 days post-treatment in plasma and gastrointestinal tract. Ivermectin concentration was higher after subcutaneous compared to per os injection in most of the tissue examined. In skin, hair and subcutaneous adipose tissue ivermectin persisted at significant concentrations 17 days post-treatment for both routes of administration. In our experimental conditions, ivermectin provides similar efficacy against T. colubriformis after subcutaneous or per os administration in goat. However, the lower ivermectin levels in tissues after per os administration suggest that the lasting of efficacy may be shortened after per os compared to subcutaneous administration especially in animals with poor body condition in pasture where re-infection occurs quickly after anthelmintic treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15740862     DOI: 10.1016/j.vetpar.2004.11.028

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  16 in total

1.  Ivermectin and COVID-19: Keeping Rigor in Times of Urgency.

Authors:  Carlos Chaccour; Felix Hammann; Santiago Ramón-García; N Regina Rabinovich
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

2.  Ivermectin-loaded lipid nanocapsules: toward the development of a new antiparasitic delivery system for veterinary applications.

Authors:  G V Ullio Gamboa; S D Palma; A Lifschitz; M Ballent; C Lanusse; C Passirani; J P Benoit; D A Allemandi
Journal:  Parasitol Res       Date:  2016-02-06       Impact factor: 2.289

3.  Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptes scabiei in the Porcine Scabies Model for Human Infestation.

Authors:  Charlotte Bernigaud; Fang Fang; Olivier Chosidow; Jacques Guillot; Katja Fischer; Anne Lespine; Ludwig S Aho; Amanda J Mullins; Berhane Tecle; Andrew Kelly; Jean-François Sutra; Francis Moreau; Thomas Lilin; Frédéric Beugnet; Françoise Botterel
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  In vivo protection against strychnine toxicity in mice by the glycine receptor agonist ivermectin.

Authors:  Ahmed Maher; Rasha Radwan; Hans-Georg Breitinger
Journal:  Biomed Res Int       Date:  2014-09-15       Impact factor: 3.411

5.  Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model.

Authors:  Charlotte Bernigaud; Fang Fang; Katja Fischer; Anne Lespine; Ludwig Serge Aho; Dominique Dreau; Andrew Kelly; Jean-François Sutra; Francis Moreau; Thomas Lilin; Françoise Botterel; Jacques Guillot; Olivier Chosidow
Journal:  PLoS Negl Trop Dis       Date:  2016-10-12

6.  A field study on the efficacy of ivermectin via subcutaneous route against chewing lice (Bovicola caprae) infestation in naturally infested goats.

Authors:  Y Ajith; Umesh Dimri; A Gopalakrishnan; Gopinath Devi
Journal:  Onderstepoort J Vet Res       Date:  2019-01-30       Impact factor: 1.792

7.  The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.

Authors:  Kushal Banerjee; Manab Nandy; Chanchal Kumar Dalai; Shah Newaz Ahmed
Journal:  Drug Res (Stuttg)       Date:  2020-06-19

8.  Gastrointestinal nematodes and anthelmintic resistance in Danish goat herds.

Authors:  Signe A Holm; Camilla R L Sörensen; Stig M Thamsborg; Heidi L Enemark
Journal:  Parasite       Date:  2014-07-31       Impact factor: 3.000

9.  Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19?

Authors:  Niti Mittal; Rakesh Mittal
Journal:  Med Hypotheses       Date:  2020-11-05       Impact factor: 1.538

10.  The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.

Authors:  Virginia D Schmith; Jie Jessie Zhou; Lauren R L Lohmer
Journal:  Clin Pharmacol Ther       Date:  2020-06-07       Impact factor: 6.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.